Business Context and Reporting Period
Filing: Form 10-K for the fiscal year ended December 31, 2017, filed March 13, 2018. The supplied filing is for Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc.; this company-identity mismatch should be verified.
Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare genetic diseases and cancer. Its lead candidate, pegzilarginase (AEB1102), was being evaluated for Arginase 1 Deficiency and arginine-dependent cancers. The company had no approved products and no product sales; all reported revenue came from a CPRIT research grant.
Financial and Operating Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Grant revenue | $5.2 million | $4.6 million | +12% |
| Research and development expense | $22.8 million | $18.1 million | +26% |
| General and administrative expense | $10.1 million | $8.4 million | +20% |
| Total operating expenses | $32.9 million | $26.5 million | +24% |
| Loss from operations | $(27.7) million | $(21.9) million | Loss increased 26% |
| Net loss | $(27.2) million | $(21.7) million | Loss increased 26% |
| Net loss per share | $(1.80) | $(2.22) | Improved due primarily to higher share count |
| Operating cash flow | $(24.6) million | $(18.8) million | Cash use increased |
| Capital expenditures | $0.6 million | $0.2 million | Increased |
| Cash, cash equivalents and marketable securities | $50.3 million | $63.5 million | Decreased $13.2 million |
| Total liabilities | $5.7 million | $4.1 million | Increased |
Gross or operating margins are not meaningful because revenue consisted solely of grant revenue and the company remained loss-making. The company reported no debt or credit facility and stated that it had no additional committed capital. Working capital was $49.4 million, accumulated deficit was $72.5 million, and total assets were $56.1 million.
Financing activities provided $12.2 million in 2017, including $11.4 million of net proceeds from a June 2017 follow-on offering of 3.0 million shares. The company also had up to $20.0 million available under an at-the-market offering, with no sales under that facility through December 31, 2017.
Material Changes Versus the Prior Comparable Period
- R&D spending increased $4.7 million, driven by higher personnel, manufacturing, and clinical-development costs. Nonclinical spending declined after completion of certain toxicology work in 2016.
- G&A expense increased $1.7 million because of higher compensation, consulting, facility, and public-company costs.
- Grant revenue rose $0.6 million as cancer clinical-trial costs increased, but the company remained dependent on grant funding rather than commercial revenue.
- Operating cash use increased $5.8 million to $24.6 million. The company also increased purchases of marketable securities and ended the year with substantially less cash and securities than in 2016.
- The company advanced pegzilarginase clinical programs, including the Phase 1/2 Arginase 1 Deficiency study, solid-tumor cohort expansions, and preparation for a pembrolizumab combination study in small-cell lung cancer.
- Development in AML and MDS was discontinued in December 2017 because no significant clinical activity or evidence of clinical benefit was observed.
- At year-end, the company had 16.7 million common shares outstanding, compared with 13.4 million at December 31, 2016.
Guidance, Outlook, Risks and Unusual Items
Management estimated that existing cash, cash equivalents, and marketable securities would fund operations through September 30, 2019 under its then-current operating plan. Management also stated that additional financing would be required to conduct all planned research and development activities. The estimate was subject to clinical, regulatory, manufacturing, enrollment, and spending risks.
- Pegzilarginase remained in early-stage clinical development, and no product candidate had received regulatory approval.
- The company expected operating losses to continue and potentially increase as clinical trials, manufacturing, biomarker work, pipeline development, and public-company expenses expanded.
- The Phase 1 solid-tumor program established a maximum tolerated dose of 0.33 mg/kg weekly; reversible rash and tremor were observed at 0.40 mg/kg per week. Two dose-limiting toxicities were reported.
- In the Arginase 1 Deficiency program, the FDA requested additional information before pediatric enrollment; the company later reached agreement on an age-tiered pediatric protocol. A pediatric patient subsequently experienced an infusion-associated reaction with related serious adverse events.
- The company relied on third parties for clinical research, manufacturing, supply, and potential companion diagnostics, creating execution and supply-chain risks.
- The CPRIT grant was capped at $19.8 million, with $12.9 million collected through year-end and $3.1 million recorded as a grant receivable. The grant contract expired May 31, 2018 and includes potential low- to mid-single-digit royalty obligations on future related revenue.
- University license agreements could require up to $6.4 million in milestone payments per covered product, including payments upon regulatory approval, plus low-single-digit royalties and potential sublicense revenue sharing.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2017, although the independent auditor was not required to provide an internal-control attestation because of the company’s emerging-growth-company status.
Most Important Facts for Investors to Verify
- Verify the issuer identity: the filing text is for Aeglea BioTherapeutics, Inc., while the request identifies Spyre Therapeutics, Inc.
- Confirm current liquidity, cash runway, financing activity, and dilution since December 31, 2017.
- Verify subsequent clinical results, regulatory interactions, safety findings, and the status of pegzilarginase programs.
- Assess whether grant revenue ended or was replaced by other funding, since the company had no product revenue.
- Review the potential impact of University milestones, royalties, CPRIT royalties, manufacturing commitments, and other contingent obligations.
- Confirm the status of the discontinued AML/MDS program and whether any additional programs were deprioritized.